Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 33 of 99

  1. DEADA-07-23

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  2. DEB025

    ENANTA PHARMACEUTICALS INC

    Hepatitis C Virus

    phase 1 small molecule completed

    1 trial

  3. DELAY

    The George Institute

    Lynch Syndrome

    phase 1 other active

    1 trial

  4. DEUCR-07-25

    Lacuna Pharma Pty Ltd

    plaque psoriasis

    phase 1 other active

    1 trial

  5. DEUCR-08-25

    Lacuna Pharma Pty Ltd

    plaque psoriasis

    phase 1 other active

    1 trial

  6. DF-003

    BRIGHT MINDS BIOSCIENCES INC.

    ROSAH

    phase 1 small molecule active

    1 trial

  7. DF-006-1001

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  8. DF2755A-HV-101

    Dompe' Farmaceutici S.p.A.

    interstitial cystitis/bladder pain syndrome

    phase 1 other active

    1 trial

  9. DFUPS

    United Therapeutics Europe Ltd

    Diabetic Foot

    phase 1 other completed

    1 trial

  10. DHAP

    Takeda

    Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  11. DISC-0974

    Disc Medicine

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  12. DISC-0974

    Disc Medicine

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

  13. DISC-3405

    Disc Medicine

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  14. DISC-3405

    Disc Medicine

    Sickle Cell Disease

    phase 1 small molecule active

    1 trial

  15. DITEST

    NEUROCRINE BIOSCIENCES INC

    Male Hypogonadism

    phase 1 small molecule completed

    1 trial

  16. DM199

    DiaMedica Therapeutics

    Chronic Kidney Disease

    phase 1 small molecule completed

    1 trial

  17. DMPA

    United Therapeutics Europe Ltd

    Contraception

    phase 1 small molecule completed

    1 trial

  18. DMT in healthy subjects

    Lacuna Pharma Pty Ltd

    Stroke

    phase 1 other active

    1 trial

  19. DNL151

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. DNL201

    Denali Therapeutics

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  21. DNL201

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  22. DNL343

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  23. DNL628

    Denali Therapeutics

    Alzheimer Disease, Early Onset

    phase 1 small molecule active

    1 trial

  24. DNL747

    Denali Therapeutics

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  25. DNL747

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule terminated

    1 trial

  26. DNL919

    Denali Therapeutics

    Healthy Participant

    phase 1 small molecule completed

    1 trial

  27. DNL952

    Denali Therapeutics

    Late-onset Pompe Disease

    phase 1 small molecule active

    1 trial

  28. DNLI-K-0001

    Denali Therapeutics

    Early Alzheimer's Disease

    phase 1 other active

    1 trial

  29. DP CD8 TIL

    Phio Pharmaceuticals

    HNSCC

    phase 1 mab active

    1 trial

  30. DPH001-01

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  31. DPH001-01

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  32. DS-1205c

    Daiichi Sankyo

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule terminated

    1 trial

  33. DS101-CT-01

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  34. DS101-CT-01

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  35. DS1062-A-U102

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  36. DS3201-324

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  37. DS8201-A-U106

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  38. DSE-BMP-0001-CIS-MA

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  39. DSE-BMP-0002-CIS-MA

    Daiichi Sankyo

    No medical condition

    phase 1 other active

    1 trial

  40. DSE-BMP-0003-CIS-MA

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  41. DSE-BMP-0004-CIS-MA

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  42. DSM265

    United Therapeutics Europe Ltd

    Healthy

    phase 1 small molecule completed

    1 trial

  43. DSP loaded RBC using EryDex System

    Quince Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  44. DT-216

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 1 small molecule completed

    2 trials

  45. DT2216

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  46. DV0012

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  47. Dabigatran

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 1 small molecule terminated

    1 trial

  48. Dabigatran Etexilate

    CORCEPT THERAPEUTICS INC

    Cushing Syndrome

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.